Investor Roivant Sciences Ltd.
13D/G Filings

This page shows a list of all the recent 13D/G filings made by Roivant Sciences Ltd. . Schedule 13D is commonly referred to as a “beneficial ownership report.” The term "beneficial owner" is defined under SEC rules. It includes any person who directly or indirectly shares voting power or investment power (the power to sell the security).

When a person or group of persons acquires beneficial ownership of more than 5% of a voting class of a company’s equity securities, they are required to file a Schedule 13D within ten days after the purchase. Click the link icon to see the full transaction history.

Add This Fund
to your dashboard

Date Form Target Prev
Shares		 Current
Shares		 Change
(Percent)		 Ownership
(Percent)		 Change
(Percent)
2025-04-21 13D/A IMVT / Immunovant, Inc. 96,660,341 96,660,341
2025-02-25 13D/A ABUS / Arbutus Biopharma Corporation 38,847,462 38,847,462
2025-02-18 13D/A ABUS / Arbutus Biopharma Corporation 38,847,462 38,847,462
2025-01-15 13D/A IMVT / Immunovant, Inc. 79,815,331 96,660,341
2023-10-04 13D/A IMVT / Immunovant, Inc. 73,398,664 79,815,331
2021-10-20 13D/A ABUS / Arbutus Biopharma Corporation 16,013,540 38,847,462
2021-08-02 13D/A IMVT / Immunovant, Inc. 56,377,388 73,398,664
2021-03-08 13D/A IMVT / Immunovant, Inc. 56,377,388 56,377,388
2020-09-18 13D/A IMVT / Immunovant, Inc. 47,603,419 56,377,388
2020-09-04 13D/A IMVT / Immunovant, Inc. 47,223,419 47,603,419
2020-05-15 13D/A IMVT / Immunovant, Inc. 47,223,419 47,223,419
2020-05-14 13D/A IMVT / Immunovant, Inc. 38,449,450 47,223,419
2020-04-17 13D/A IMVT / Immunovant, Inc. 38,449,450
2020-02-28 13D/A SIOX / Sio Gene Therapies Inc. 13,244,047 18,577,380
2019-12-31 13D/A MYOV / Myovant Sciences Ltd 44,509,411 0
2019-12-31 13D/A UROV / Urovant Sciences Ltd 22,860,013 0
2019-12-31 13D/A SIOX / Sio Gene Therapies Inc. 13,244,047 13,244,047
2019-12-20 13D IMVT / Immunovant, Inc. 37,414,967
2019-11-27 13D/A MYOV / Myovant Sciences Ltd 40,765,599 44,509,411
2019-11-04 13D/A MYOV / Myovant Sciences Ltd 40,765,599 40,765,599
2019-11-04 13D/A UROV / Urovant Sciences Ltd 22,860,013 22,860,013
2019-09-06 13D/A MYOV / Myovant Sciences Ltd 40,765,599 40,765,599
2019-09-06 13D/A UROV / Urovant Sciences Ltd 22,860,013 22,860,013
2019-09-06 13D/A SIOX / Sio Gene Therapies Inc. 13,244,047 13,244,047
2019-07-16 13D/A MYOV / Myovant Sciences Ltd 40,765,599 40,765,599
2019-07-16 13D/A ABUS / Arbutus Biopharma Corporation 16,013,540 16,013,540
2019-07-16 13D/A SIOX / Sio Gene Therapies Inc. 105,952,381 13,244,047
2019-07-16 13D/A UROV / Urovant Sciences Ltd 22,703,669 22,860,013
2019-06-14 13D MYOV / Myovant Sciences Ltd 38,341,357 40,765,599
2019-03-19 13D/A SIOX / Sio Gene Therapies Inc. 99,285,714 105,952,381
2019-02-13 13G/A MYOV / Myovant Sciences Ltd 37,231,342 38,341,357
2018-12-20 13D/A SIOX / Sio Gene Therapies Inc. 89,285,714 99,285,714
2018-10-10 13D UROV / Urovant Sciences Ltd 22,703,669
2018-06-15 13D SIOX / Sio Gene Therapies Inc. 75,000,000 89,285,714
2018-04-23 13D/A ABUS / Arbutus Biopharma Corporation 16,013,540 16,013,540
2018-04-12 13D/A ABUS / Arbutus Biopharma Corporation 16,013,540 16,013,540
2018-03-16 13D/A ABUS / Arbutus Biopharma Corporation 16,013,540 16,013,540
2018-02-14 13D/A ABUS / Arbutus Biopharma Corporation 16,013,540 16,013,540
2018-01-16 13D/A ABUS / Arbutus Biopharma Corporation 16,013,540 16,013,540
2017-10-17 13D/A ABUS / Arbutus Biopharma Corporation 16,013,540 16,013,540
2017-10-03 13D/A ABUS / Arbutus Biopharma Corporation 16,013,540 16,013,540
2017-02-10 13G MYOV / Myovant Sciences Ltd 37,231,342
2016-02-17 13D/A ABUS / Arbutus Biopharma Corporation 16,075,955 16,013,540
2016-02-16 13G SIOX / Sio Gene Therapies Inc. 75,000,000
2015-08-26 13D/A ABUS / Arbutus Biopharma Corporation 16,068,455 16,075,955
2015-03-16 13D ABUS / Arbutus Biopharma Corporation 16,068,455